anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A sleep quality evaluation system and method are provided in the present disclosure. The sleep quality assessment system includes a database and an electronic device. The electronic device selects a selected content information from a plurality of content information in the database, and provides the selected content information to a user for evaluation. The electronic device receives a first evaluation information and a second evaluation information of the user. The user performs a sleep activity between the first time and the second time. The electronic device compares the first evaluation information of the user with the second evaluation information to generate a sleep quality parameter of the user.
BACKGROUND: Pancreatic cancer is known for its poor prognosis and resistance to conventional therapies, largely due to the presence of cancer stem cells (CSCs) and aggressive angiogenesis. Effectively targeting these CSCs and associated angiogenic pathways is crucial for effective treatment. This study leverages single-cell multi-omics to explore a novel therapeutic approach involving Chimeric Antigen Receptor (CAR) macrophages engineered to target the c-Met protein on pancreatic CSCs.
METHODS: We employed single-cell RNA sequencing to analyze pancreatic cancer tissue, identifying c-Met as a key marker of CSCs. CAR macrophages were engineered using a lentiviral system to express a c-Met-specific receptor. The phagocytic efficiency of these CAR macrophages against pancreatic CSCs was assessed in vitro, along with their ability to inhibit angiogenesis. The in vivo efficacy of CAR macrophages was evaluated in a mouse model of pancreatic cancer.
RESULTS: CAR macrophages demonstrated high specificity for c-Met + CSCs, significantly enhancing phagocytosis and reducing the secretion of angiogenic factors such as VEGFA, FGF2, and ANGPT. In vivo, these macrophages significantly suppressed tumor growth and angiogenesis, prolonging survival in pancreatic cancer-bearing mice.
CONCLUSION: CAR macrophages targeting c-Met represent a promising therapeutic strategy for pancreatic cancer, offering targeted elimination of CSCs and disruption of tumor angiogenesis. This study highlights the potential of single-cell multi-omics in guiding the development of precision immunotherapies.
The present invention relates to neuronal formation and methods of treating diseases characterized by abnormalities in the activity of dopaminergic (DA) and serotonergic (5HT) neurons. In particular, the invention relates to a method of forming serotonergic neurons in vitro by contacting neuroprogenitor cells to an effective amount of native sequence, variants and functional fragments of FGF-4, FGF-8 and Shh. Additionally, disclosed is a method for forming dopaminergic neurons by contacting neuroprogenitor cells to an effective amount of FGF-8 and Shh. Further described are compositions, cell culture compositions and medical devices which contain sufficient amount of FGF-8, Shh or FGF-8, Shh and FGF-4 to stimulate differentiation into dopaminergic or serotonergic neurons, respectively. Further described are methods of using serotoneurgic neurons to treat disorders relating to food intake, hormone secretion, stress response, pain and immune function, sexual activity, cardiovascular function and temperature regulation, in particular, depression, proclivity to suicide, violent aggressive behavior, obsessive-compulsive behavior and anorexia/bulimia and schizophrenia. Further described are methods of using dopaminergic neurons to treat disorders relating postural reflexes, movement and reward-associated behaviors, specifically, Parkinson's disease, schizophrenia and drug addiction. Further described is the coadministration of a neuronal survival factor, for example, NGF, CNTF, BDNF, NT-3, NT-4, aFGF, IL-1beta, TNFalpha, IGF-1, IGF-2, TGF-beta, TGF-beta1 or skeletal muscle extract.
FIELD: magnetic resonance visualization of image. SUBSTANCE: method of magnetic resonance examination of specimen, preferably organism of man or animal, includes preparation of hyperpolarized solution of agent with high T 1  by solution of hyperpolarized solid specimen of mentioned agent with high T 1  in physiologically allowable solvent. Operations of hyperpolarization of solid specimen of mentioned agent with high T 1  by means of polarizing agent include: a) separation of all, practically all or portion of mentioned polarizing agent with high T 1 ; b) injection of mentioned hyperpolarized solution into mentioned specimen; c) irradiation of mentioned specimen by second radiator with frequency chosen for excitation of nuclear spin transitions in selected nuclei, for example, in nuclei of magnetic resonance agent with high T 1 ; d) recording of magnetic resonance signals from mentioned specimen and e) winning of image, dynamic data flow, diffusion parameters, perfusion parameters, physiological parameters ( for instance, pH, pO 2 , pCO 2 , temperature or ion concentration ) or metabolic parameters from mentioned recorded signals. Mentioned agent with high T 1  in mentioned hyperpolarized solution has value T 1  ( with field intensity in range 0.01- 5.0 Tm and temperature between 40-and 60 C ) for at least 5.0 s. Formula of invention gives description of composition and contrast medium which are utilized as agent with high time of longitudinal relaxation T 1 . EFFECT: raised quality of visualization of image. 34 cl, 5 dwg
Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
PURPOSE:To provide the titled vitamin complex free from the segregation of the active component and resistant to the degradation with time, by solidifying a tocopherol carboxylic acid ester mainly with gelatin in the form of beads, and filling the beads and fine crystals of ascorbic acid in a hard gelatin capsule in layers. CONSTITUTION:Beads of tocopherol carboxylic acid ester (e.g. alpha-d-tocopherol acetate) solidified by using gelatin as a main binder and fine crystals of ascorbic acid are filled in a hard gelatin capsule in layers to obtain the objective vitamin CE complex. The ratio of tocopherol to ascorbic acid is 1:5 to maximize the drug action as an antioxidant, and 50mg of vitamin E and 250mg of vitamin C are filled in one capsule. Preferably, vitamin C crystals are filled in the bottom of the capsule, and then, the vitamin E beads are put thereon. There is little variation of the content caused by segregation, and the change of appearance during the transportation and storage can be prevented.
The invention provides a polypeptide of a targeted neovascular marker CD105 and application thereof. The polypeptides CD1051 and CD1052 provided by the invention can be specifically combined with CD105 protein, and the polypeptides can be applied to CD105 positive vascular endothelial cells and the like instead of CD105 antibodies, and can also be used for preparing in vivo targeted tumor imaging or visualization preparations. The polypeptide and an anti-tumor drug or other reagents form a conjugate, and the conjugate can target CD105 protein and be used for anti-angiogenesis tumor treatment. In addition, the method can reflect the change of new vessels in cardiovascular system diseases, and plays an important role in the diagnosis and prognosis judgment of atherosclerosis. The polypeptide of the invention has good specificity and sensitivity, simple preparation method, low cost and strong practicability. The invention provides a simple, convenient, rapid, economic and accurate detection means for monitoring the in-vivo CD105 expression of a patient and the correlation of tumor grading, staging, metastasis and prognosis in real time.
Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, 8 weeks.
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
Management of collections of medical documents is provided. In various embodiments, search criteria are specified for one or more datastore. Location information for a plurality of medical documents (e.g. images, textual documents, time series data, etc.) is retrieved from the one or more datastore. The location information for the plurality of medical documents is aggregated into a virtual collection. The virtual collection is indexed by metadata of the virtual collection.
The formation of fibrotic tissue, characterized by the excessive accumulation of extracellular matrix (ECM) components such as collagen and fibronectin, is a normal and crucial stage of tissue repair in all organs. The over-synthesis, deposition, and remodeling of ECM components lead to organ dysfunction, posing a significant medical burden. Berberine, an isoquinoline alkaloid, is commonly used in the treatment of gastrointestinal diseases. With the deepening of scientific research, it has been gradually discovered that berberine also plays an important role in fibrotic diseases. In this review, we systematically introduce the effective role of berberine in fibrosis-related diseases. Specifically, this paper aims to provide a comprehensive review of the therapeutic role of berberine in treating fibrosis in organs such as the heart, liver, lungs, and kidneys. By summarizing its various pathways and mechanisms of action, including the inhibition of the transforming growth factor-[Formula: see text]/Smad signaling pathway, PI3K/Akt signaling pathway, MAPK signaling pathway, RhoA/ROCK signaling, and mTOR/p70S6K signaling pathway, as well as its activation of the Nrf2-ARE signaling pathway, AMPK signaling pathway, phosphorylated Smad 2/3 and Smad 7, and other signaling pathways, this review offers additional evidence to support the treatment of fibrotic diseases.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the pivotal placebo-controlled, double-blind study (ENVISION), 48 patients received 2.5 mg/kg GIVLAARI and 46 patients received placebo, administered once monthly via subcutaneous injection for up to 6 months. Patients received GIVLAARI for a median of 5.5 months (range 2.7-6.4 months). Of these, 47 patients received ≥5 months of treatment. The most frequently occurring (≥20% incidence) adverse reactions reported in patients treated with GIVLAARI were nausea (27%) and injection site reactions (25%). Permanent discontinuation occurred in one patient due to elevated transaminases.

Adverse reactions observed at a lower frequency occurring in placebo-controlled and open-label clinical studies included anaphylactic reaction (one patient, 0.9%) and hypersensitivity (one patient, 0.9%).

In the ENVISION study, during the open label extension, adverse reactions of blood homocysteine increased were reported in 15 of 93 (16%) patients treated with GIVLAARI [see Warnings and Precautions (5.5)].
Injuries from falls are a leading cause of emergency visits, hospitalizations, and deaths in older US adults, resulting in total lifetime costs of more than $19 billion in 2000. Fall injuries reduce independence and mobility, and increase disability and institutionalization. There is good evidence that community-based group exercise classes focusing on strength and balance prevent older adult falls, but uptake is limited. This study will test a new approach to promote participation in group balance-retraining exercise classes, targeting older adults in faith-based congregations. The proposal addresses national research priorities to evaluate strategies for dissemination and implementation of effective interventions to prevent falls among community-dwelling older adults. Focus groups and key informant interviews will provide research-based understanding of church members aged 60+ and those who influence them, and explore facilitators and barriers to class participation. With this formative research, a targeted social marketing program will be developed to motivate participation. Behavioral change and social marketing theories form the intervention's theoretical basis and will guide program design. The marketing program aims to increase class attractiveness, usability, and uptake by reducing barriers or costs and using incentives or other benefits to reinforce participation. Churches, representing varied denominations and communities, will be randomly allocated to intervention (marketing program implementation) or control (no program) groups. Outreach to diverse churches will ensure that materials and strategies target potentially hard-to-reach (e.g., Hispanic, rural) populations. The trial will test whether older adult members of intervention churches are more likely to join balance retraining classes. Factors that may mediate intervention effects will be examined. Secondary outcomes include baseline fall risk among class participants, assessed by physical function tests; and intensity, diffusion, message penetration and acceptability of the marketing program, and persistent facilitators and barriers to class participation, evaluated with process measures, focus groups, and structured interviews.
Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
PURPOSE:To obtain a hair cosmetic having excellent effect for giving smooth and moist hair which can be combed easily, by using specific amounts of a mono-N-(long chain acyl) basic amino acid lower alkyl ester salt and a natural oil or amino acid as the components. CONSTITUTION:A hair cosmetic is compounded with 0.1-10wt%, preferably 0.2-5wt% of a mono(N-long chain acyl)basic amino acid lower alkyl ester salt (e.g. N-cocoylarginine ethyl ester pyroglutamate salt) and 0.1-10wt%, preferably 0.1-5wt% of a natural oil (e.g. squalane, minke oil, soybean oil) or an amino acid (e.g. glycine, isoleucine, or lysine). Preferably, the basic amino acid component of the mono-(N-long chain acyl) basic amino acid lower ester salt is lysine, arginine, etc., the acyl group is a 8-22C fatty acid residue, and the salt is acidic amino acid salt, or hydrochloride.
PURPOSE:To obtain a soft capsule agent stably preservable at room temperature even in a hot and humid environment in summer season, etc., without causing the adhesion of capsules by moisture and heat, etc., by using a coating film containing a water-insoluble cellulose and an inorganic acid salt. CONSTITUTION:The objective soft capsule agent can be prepared by (1) mixing gelatin, glycerol, etc., with (A) a water-insoluble cellulose or its derivative (e.g. crystalline cellulose or ethyl cellulose) and/or a water-insoluble inorganic acid salt (e.g. monobasic phosphate such as monobasic calcium phosphate, dibasic phosphate such as dibasic calcium phosphate, alkaline-earth metal salt such as precipitated CaCO3 or MgCO3, etc.) and (B) purified water at 80 deg.C for 3hr under heating to form a soft capsule coating agent consisting of a sol solution of gelatin, (2) mixing the solution with tocopherol acetate and sesame oil under stirring to obtain a homogeneous liquid mixture to be used as a content and (3) coating the content with the coating agent by a filling machine. The amount of the cellulose and inorganic acid is 3-50 pts.wt. per 100 pts.wt. of gelatin.
<P>PROBLEM TO BE SOLVED: To provide an osteogenic treatment device having excellent osteogenesis ability.  <P>SOLUTION: This osteogenic treatment device comprises a nucleic acid containing a base sequence encoding a bone morphogenetic protein (BMP), a vector and a substrate body and is transplanted in a living body to carry out osteogenic treatment. The bone morphogenetic protein is preferably BMP-2 and the nucleic acid preferably contains an expression plasmid derived base sequence. The vector is preferably a positively charged liposome being a vector derived from a nonvirus. The form of its substrate body is preferably a block body, especially a porous body having 30-95% porosity. The constituent material of the substrate body is a material consisting essentially of hydroxyapatite or tricalcium phosphate.  <P>COPYRIGHT: (C)2004,JPO
The purpose of this substudy is to learn more about maternal use of antibiotics in women who do or do not breastfeed, and how this may influence infant and child health. Women who contact or are referred to the UCSD Human Milk Biorepository will be screened to participate in the Antibiotic Exposure sub-study. Women will be eligible to enroll in the Antibiotic Exposure sub-study if they are 18 years of age or older, have a singleton infant who is \<3 months of age at the time of recruitment, and agree to all requirements of the study.
OBJECTIVES: Metastatic prostate cancer is the most common malignant cancer and the second leading cause of death due to various types of cancer among men after lung cancer. This study aimed to analyze the cost-effectiveness of triptorelin, goserelin, and leuprolide in the treatment of the patients with metastatic prostate cancer from the societal perspective in Iran in 2020.
METHODS: This is a cost-effectiveness study in which a 20-year Markov transition modeling was applied. In this study, local cost and quality-of-life data of each health state were gathered from cohort of patients. The TreeAge pro 2020 and Microsoft Excel 2016 software were used to simulate cost-effectiveness of each treatment in the long term. The one-way and probabilistic sensitivity analyses were also performed to measure robustness of the model outputs.
RESULTS: The findings indicated that the mean costs and utility gained over a 20-year horizon for goserelin, triptorelin, and leuprolide treatments were $ 13 539.13 and 6.365 quality-adjusted life-years (QALY), $ 18 124.75 and 6.658 QALY, and $ 26 006.92 and 6.856 QALY, respectively. Goserelin was considered as a superior treatment option, given the estimated incremental cost-effectiveness ratio. The one-way and probabilistic sensitivity analyses confirmed the robustness of the study outcomes.
CONCLUSIONS: According to the results of the present study, goserelin was the most effective and cost-effective strategy versus 2 other options. It could be recommended to policy makers of the Iran healthcare system to prioritize it in clinical guidelines and reimbursement policies.
Benign and malignant diseases of the upper gastrointestinal tract show gender-specific differences. The frequent gastroesophageal reflux disease is a prime example: men have an erosive reflux disease more often than women and are also younger at the time of onset. The rate of progression to a metaplastic Barrett's esophagus is also higher in men. In the case of achalasia, there are indications that surgical treatment by laparoscopic Heller's myotomy and semifundoplication 180° according to Dor leads to a markedly better improvement in the symptoms in women compared to men, although they showed a more pronounced dilation of the tubular esophagus. The female hormone status influences the localization and histopathology of adenocarcinoma of the esophagogastric junction and gastric carcinoma. Premenopausal and postmenopausal carcinomas differ significantly in women. In addition, high microsatellite instability (MSI high) is more frequent in women and is associated with a generally significantly better prognosis. The MSI high gastric carcinomas of women show better survival than MSI high carcinomas of men. The future inclusion of gender-specific aspects in studies of the upper gastrointestinal tract is desirable in order to generate adequate data and to enable differentiated treatment stratification in the future.
Nitroglycerin: Isradipine has been safely coadministered with nitroglycerin. 

Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of isradipine and hydrochlorothiazide does not result in altered pharmacokinetics of either drug. In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. 

Propranolol: In a single dose study in normal volunteers, co-administration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability. Significant increases in AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study. However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d. propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug's bioavailability. AUC and Cmax differences were <20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine. 

Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%). If isradipine therapy is initiated in a patient currently receiving cimetidine, careful monitoring for adverse reactions is advised and downward dose adjustment may be required.

Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits. If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine. 

Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multiple-dose treatment with 5 mg b.i.d. isradipine. Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.

Digoxin:  The concomitant administration of isradipine and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin. 

Fentanyl Anesthesia:  Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker. Even though such interactions have not been seen in clinical studies with isradipine, an increased volume of circulating fluids might be required if such an interaction were to occur.